Tara K. Gregory, MD, Colorado Blood Cancer Institute, Denver, Colorado, discusses CAR T-cell therapy for multiple myeloma. Dr Gregory reviews steps involved in CAR T-cell therapy, potential outcomes and risks, the impact on quality of life, and which patients may be good candidates for CAR T-cell therapy.
Doris Hansen, MD, Moffitt Cancer Center, Tampa, Florida, discusses an analysis of pretreatment biomarkers associated with toxicity and durable response related to idecabtagene vicleucel therapy for patients with…
Roughly 30,000 Americans are diagnosed with multiple myeloma each year—a rare but serious cancer of the plasma cells. Historically treated with chemotherapy, patients often faced recurring disease and…
Patrick Connor Johnson, MD, Massachusetts General Hospital, Boston, Massachusetts, discusses real-world outcomes following treatment with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Dr Johnson notes the…
Michael Wang, MD, professor, Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses results from the TRANSCEND-NHL-001 study, which was designed to investigate…
Barry Paul, MD, Atrium Health Levine Cancer Institute, Charlotte, North Carolina, discusses research related to idecabtagene vicleucel treatment for patients with newly diagnosed multiple myeloma and suboptimal responses…
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses findings from one arm of the Phase 2 KarMMA-2 trial that was designed to investigate idecabtagene vicleucel in…
Bhavesh Mohan Lal, MD, UAMS College of Medicine, Little Rock, Arkansas, reviews a study designed to investigate the effects of prior exposure to BCMA-targeting agents on outcomes with…
Manali Kamdar, MD, clinical director of lymphoma services, University of Colorado Cancer Center, Denver, Colorado, discusses the use of circulating tumor DNA as an early predictor of outcomes…
In an interview recorded during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Luciano Costa, MD, PhD, of UAB School of Medicine, Birmingham, AL,…
Teri Foy, PhD, Senior Vice President, Cancer Immunology and Cell Therapy Thematic Research Center and Seattle site lead, and Mike Burgess, MD, PhD, Senior Vice President, Head of…